share_log

Dr. Reddy's Subsidiary Aurigene Oncology, Announced Phase 1 Results For Ribrecabtagene Autoleucel From SWASTH Study; All 8 Patients Achieved Clinical Response

Dr. Reddy's Subsidiary Aurigene Oncologyは、SWASTH StudyからRibrecabtagene Autoleucelの第1相結果を発表しました。全セクターの8人の患者が臨床的反応を達成しました。

Benzinga ·  10/08 06:29

Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study – India's first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. The study reported initial results from the first 8 patients. All patients were heavily pre-treated with median of 5.5 previous lines of treatment. Most patients had also received transplant in the past and had disease progression post-transplant. All 8 patients (100%) achieved clinical response, with 5/8 (62.5%) having achieved stringent complete response. With respect to safety, there were no high-grade events of Cytokine Release Syndrome (CRS) or neurotoxicity, in any of the patients.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする